INTRODUCTION
Gastric cancer is the second leading cause of cancer-related deaths world-wide, with the primary risk factor being persistent gastric inflammation (gastritis) caused by colonisation with the pathogen Helicobacter pylori.
1 Although all H. pylori-colonized individuals show some level of gastritis, only 2.9% of gastritis patients will develop gastric cancer, 2 implying that additional host factors contribute to the progression of gastritis to gastric cancer. In this regard, much attention in recent years has focussed on the role of pathogen recognition receptors, in particular the toll-like receptor (TLR) family, as potential facilitators of gastrointestinal carcinogenesis. TLR2 and TLR4 have been most heavily implicated in human gastric cancer, largely based on their reported ability to recognise Helicobacter pylori bacterium, increased expression in inflamed tissue biopsies from gastritis and gastric cancer patients, and gene polymorphisms linked to increased gastric cancer risk. [3] [4] [5] [6] [7] With respect to TLR2, we have recently reported a specific requirement for TLR2 in the development of gastric tumours in the gp130 F/F preclinical mouse model of gastritis and gastric cancer. 3 Furthermore, upregulated TLR2 gene expression in gastric cancer tumour biopsies correlated with impaired patient survival rates. 3 Somewhat surprisingly, the tumourigenic potential of TLR2 signalling was independent of its capacity to trigger inflammation, but rather involved promoting proliferation and survival of gastric cancer (epithelial) cells. 3 Among the TLR family, TLR2 recognises and responds to the broadest repertoire of ligands, largely due to its formation of heterodimeric complexes with either TLR1 or TLR6, and utilisation of the coreceptors CD14 and CD36. [8] [9] The classical model of TLR2 signalling involves both the adapter proteins myeloid differentiation factor 88 (MyD88) and Mal (also called TIR-domain containing adapter protein (TIRAP)), which lead to the activation of nuclear factor kappa B (NF-kB), as well as p38, extracellular-regulated kinase and c-Jun N-terminal kinase mitogen-activated protein kinase (MAPK) pathways. 10 However, recent in vitro studies in macrophages suggest that, unlike the essential role of MyD88 in the TLR2-induced activation of NF-kB and mitogen-activated protein kinase signalling, Mal is primarily required for the TLR2-dependent activation of these signalling cascades in response to low-ligand concentrations. [11] [12] [13] A differential requirement for Mal in TLR2 signalling also extends to activation of the phosphoinositide-3-kinase/Akt pathway, where signalling through TLR2/6, but not TLR1/2 heterodimers, requires Mal. [11] [12] [13] [14] The complexities underlying the molecular basis for TLR2-induced activation of phosphoinositide-3-kinase/Akt signalling are further exemplified 1 by contradictory reports on the dependence on MyD88 for the TLR2/phosphoinositide-3-kinase/Akt signalling axis. 11, 15 Numerous experimentally-induced tumour models for colon, skin and liver cancer involving MyD88-deficient mice have demonstrated a protumourigenic role for MyD88, although the upstream TLR(s) involved were not identified. [16] [17] [18] [19] [20] In addition, it remains unknown whether Mal also has a pivotal role in vivo in the pathogenesis of cancers. To address these issues, in this report we have employed the gp130 F/F mouse model of TLR2-mediated gastric tumourigenesis, where interleukin (IL)-11-induced hyperactivation of the Janus kinase/signal transducer and activator of transcription (STAT)-3 signalling pathway upregulates TLR2 expression in a disease-associated manner. 3, [21] [22] Here, we find that genetic ablation of Myd88 in gp130 F/F mice suppressed tumour development independent of inflammation, comparable to that previously observed upon deletion of the Tlr2 gene in gp130 F/F mice. By contrast, deletion of the Mal gene in gp130 F/F mice conferred no effect on gastric inflammation and tumourigenesis. This work therefore reveals a differential requirement in vivo for Mal and MyD88 in TLR2 signalling in the context of gastric tumourigenesis.
RESULTS AND DISCUSSION
MyD88, but not Mal, is required for gastric tumourigenesis in gp130 F/F mice To define a role for MyD88 and Mal in TLR2-mediated gastric tumourigenesis, 3 we undertook a genetic approach and examined 
:Myd88
À / À mice was similar to that previously reported for the gp130
À / À mice, 3 these observations suggest that MyD88 rather than Mal, has a key role downstream of TLR2 in facilitating gastric tumourigenesis.
We have previously shown that the reduced tumour formation in gp130
À / À mice is independent of a reduction in IL-11-driven STAT3 hyperactivation, which is consistent with the IL-11/STAT3 signalling axis being an upstream regulator of TLR2 expression in the gastric compartment. 3 To determine whether the reduced tumourigenesis in gp130 F/F :Myd88 À / À mice was also independent of alterations to IL-11-induced STAT3 signalling, we compared IL-11 and phospho-Y 705 STAT3 (pY-STAT3) protein levels in tumour tissue from gp130 :Myd88 À / À mice. (a) Immunoblot analyses were performed as before 21 on snap-frozen gastric tissue lysates prepared from 6-month-old gp130
and matched F/F tumour tissue using the antibodies indicated. Representative blots from two mice per genotype are shown. Arrows indicate the STAT3a (top) and STAT3b (bottom) isoforms. Immunoblotting antibodies against pY-STAT3, STAT3, IL-11 and actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Proteins were visualised using the Odyssey Infrared Imaging System (LI-COR, Lincoln, NE, USA) with the appropriate secondary antibodies (Rockland, Gilbertsville, PA, USA). (b, c) Immunohistochemisty for pY-STAT3 (brown staining) in the mucosal epithelium of gastric tumour-bearing regions of 6-month-old F/F, F/F:MyD88 and F/F:Mal mice. Immunohistochemistry was performed on sections from formalin-fixed, paraffin-embedded tissue using anti-pY-STAT3 antibodies (Santa Cruz Biotechnology), and immunoperoxidase was detected with the Liquid Diaminobenzidine (DAB) Substrate Chromogen System (DakoCytomation, Carpinteria, CA, USA). Insets depict high power images of the highlighted regions (black squares) in the low power main images. Scale bars ¼ 100 mm in insets and 500 mm in main images. The graphs depict semiquantitative enumeration of the number of pY-STAT3-positive cells per Â 40 field (n410 fields) in the hyperplastic epithelium of tumour tissue, and are presented as the mean ± s.e.m. n ¼ 3-4 mice per genotype.
Gastritis in gp130
F/F mice occurs independently of Mal or MyD88
The role of MyD88 in inflammation-associated carcinogenesis is complex, as is evidenced by the numerous experimentallyinduced cancer models involving Myd88-deficient mice, which reveal that MyD88 can either promote or suppress tumour formation. For instance, whereas MyD88 protects against the development of intestinal tumours in response to azoxymethane/ dextran sodium sulphate, 24 many other studies have assigned a protumourigenic role to MyD88 in the context of carcinogeninduced models for colon, liver and skin cancer. 17, 19, 25 Although the mechanistic basis for these contrasting observations remains to be fully clarified, a likely explanation involves a combination of differences in both the upstream activators of MyD88 (that is, TLR and IL-1 family members) and cell types in which MyD88 signalling promotes disease (for example, epithelial versus bone marrow-derived immune cells). 26 In this respect, as we have previously demonstrated that activation of the STAT3-TLR2 signalling axis in the stromal compartment (comprising bone marrow-derived inflammatory/immune cell infiltrates) does not promote gastric tumourigenesis in the gp130 F/F gastric cancer mouse model, 3, 21 it is most likely that MyD88 expression in the epithelial rather than stromal compartment is important for TLR2/MyD88-mediated gastric tumourigenesis. In addition, we also note that the suppressed spontaneous intestinal tumourigenesis observed in Apc Min/ þ :Myd88 À / À mice correlates with an increased apoptotic index in intestinal polyps, which display equivalent amounts of leucocyte infiltrates as in the larger polyps from Apc Min/ þ mice. 17 This latter observation, suggesting under some circumstances a non-inflammatory role for MyD88 signalling in tumourigenesis, is further supported by our recent study demonstrating that TLR2 promotes gastric tumour growth in gp130 F/F mice independent of inflammation, 3 and the finding that MyD88 can promote Ras-mediated skin carcinogenesis in a tumour cell-autonomous manner. 20 We therefore investigated the inflammatory phenotype of stomach tissue from gp130 þ / þ ( þ / þ ), F/F, F/F:MyD88 and F/F:Mal (n ¼ 3 per genotype) mice. Single-cell suspensions of mouse tumour-bearing stomach tissue were made using collagenase digestion as described previously, 28 and flow cytometry was performed with PE-CD3 and FITC-B220 antibodies (BD Pharmingen, San Diego, CA, USA). Cells were acquired on a FACSCanto instrument (BD Biosciences, San Diego, CA, USA) and analysed using FlowJo software (Tree Star, Ashland, OR, USA). Data presented as mean±s.e.m. *Po0.05, **Po0.01. Statistical analyses were performed using one-way analysis of variance (ANOVA). Complementary DNA was prepared from total RNA from snap-frozen mouse gastric tissue, and qPCR gene expression analyses were performed on triplicate samples with SYBR Green (Invitrogen, Life Sciences, Carlsbad, CA, USA) using the 7900HT Fast RT-PCR System (Applied Biosystems) as described previously.
3 *Po0.05 using Student's t-test. (e) Lysates were prepared from snap-frozen gastric tissue from 6-month-old F/F and F/F:MyD88 mice, following which they were subjected to immunoblot analyses as previously described. 3, 22 Proteins were visualised using the Odyssey Infrared Imaging System (LI-COR, Lincoln, NE, USA) with the appropriate secondary antibodies. Densitometry quantification from four mice per genotype for the indicated phosphorylated signalling molecules, and relative expression was determined against the amount of actin protein as a loading control, and is presented as the mean ± s.e.m. **Po0.01 using Student's t-test. ns, not significant. þ / þ wild-type control mice was B and T lymphocytes, increasing approximately 6-fold and between 3-11-fold, respectively (Figures 3c and d) . Notably, the proportions of these cell types were comparable among the stomachs of gp130 (Figures  3c and d) . The proportion of macrophages and MDSCs did not significantly increase in gp130 F/F stomach tissue compared with gp130 þ / þ tissue, and no significant changes were observed in the proportions of macrophages or MDSCs in the stomach of gp130 Supplementary Figures 2a and b) . Among genetic or carcinogen-induced mouse colon and liver cancer models, the expression pattern of key MyD88-regulated proinflammatory cytokines, especially IL-6, TNFa and the T h 17-related cytokines, IL-17A and IL-23, coincides with disease severity, [16] [17] [18] 25, 27 suggesting that these cytokines may also contribute to MyD88-promoted tumourigenesis. However, no significant changes were detected in the gastric expression levels of mRNAs for Il-6 and Tnfa, as well as the neutrophil attractant chemokine Cxcl2, among gastric tumour tissue from gp130 Supplementary  Figures 3a and b) . Similarly, in support of our previous findings that the T h 17 response does not contribute to gastric tumourigenesis in gp130 F/F mice, 28 the genetic ablation of Myd88 in gp130 F/F mice does not alter the expression of genes related to the T h 17 nor for that matter the T h 1 response (Supplementary Figure 4) . Despite these observations, we confirmed that gastric-specific TLR2/Maland TLR2/MyD88-induced inflammatory responses were suppressed in gp130 Figures 3c and d) . Collectively, these data suggest that TLR2/Mal and TLR2/MyD88 signalling are not required for the in vivo production of proinflammatory cytokines during gastric tumourigenesis in gp130 F/F mice. These observations also suggest key differences in the role of IL-6, TNFa and T h 17-related cytokines downstream of MyD88 in the pathogenesis of gastric cancer versus other cancers of the digestive system, a notion which is supported by studies showing that IL-6 is dispensable for the gastric tumour phenotype in gp130 F/F mice, 21 but contributes to the intestinal hyperproliferative phenotype in gp130 F/F mice.
29
MyD88, but not Mal, promotes cell survival and proliferation in gastric epithelial tumours We have previously shown that TLR2-dependent signalling contributes to tumourigenesis in gp130 F/F mice by both promoting proliferation and inhibiting apoptosis in the gastric epithelial cell compartment. 3 The ability of TLR2 to inhibit epithelial cell apoptosis in the gastric compartment of gp130 F/F mice is somewhat reminiscent of the finding that intestinal tumours from Apc Min/ þ :Myd88
mice display increased numbers of apoptotic cells compared with tumours from parental Apc Min/ þ : Myd88 þ / þ mice. 17 To compare the requirement for MyD88 and Mal in promoting gastric anti-apoptotic and proliferative processes in gp130 F/F mice, we performed PCNA and TUNEL immunohistochemistry for proliferation and apoptosis, respectively, in tumour tissue from the various genotypes. As per our previous observations, little to no apoptotic TUNEL þ cells was observed throughout the gastric mucosal epithelium of gp130 F/F tumours (Figures 4a and b) . By contrast, increased numbers of apoptotic cells were observed in the surface epithelium of gp130 F/F :Myd88 À / À gastric tumours (Figure 4a ). Conversely, the surface epithelium of gp130
À / À gastric tumours was largely devoid of PCNA þ cells, whereas PCNA staining was apparent throughout the entire epithelium of gp130 F/F gastric tumours (Figure 4a ). While these data are consistent with the notion that MyD88 facilitates TLR2-mediated cellular proliferation and survival within the gastric tumour epithelium, the same was not true for Mal, as the staining patterns for PCNA and TUNEL in the gastric tumour epithelium of gp130 F/F and gp130
F/F
:Mal À / À mice were comparable (Figure 4b ). In further support of our in vivo observations in gp130 F/F mice that TLR2-driven gastric tumour (epithelial) cell proliferation and survival are mediated by MyD88 rather than Mal, small interfering RNA inhibition of MYD88 gene expression in human NUGC4 gastric epithelial cells significantly blocked the ability of ligands for TLR2/1 (Pam 3 Cys) and TLR2/6 (FSL-1) receptor complexes to promote cell proliferation, whereas small interfering RNA suppression of MAL gene expression had no such effect on TLR2-induced cell proliferation (Supplementary Figure 5) . In the tumours of mice, we also demonstrated that the expression level of TLR2-regulated protumourigenic genes Bcl2a1, Bcl3 and Birc3 were significantly reduced in gp130 
Tlr2
À / À gastric tumours), 3 whereas the expression of these genes in gastric tumours of gp130 F/F :Mal À / À mice was unaltered (Figures 4c and d) . Notably, the reduced expression of these genes in gp130 In conclusion, our current study supports a differential requirement for Mal and MyD88 in TLR2-mediated gastric tumourigenesis, and specifically that the function of Mal is dispensable. These observations confirm previous in vitro findings that TLR2 can signal independent of Mal. 13 Importantly, we find that gp130 mice with respect to reduced tumour burden, reduced cell proliferation and increased apoptosis in the gastric tumour epithelium, and no change to the tumoural STAT3 activation status, 3 further implying in this model that activation of the TLR2/MyD88 signalling pathway is secondary to hyperactivation of STAT3. We also note that the lack of requirement for Mal to confer the gastric phenotype of gp130 F/F mice is consistent with our previous report that TLR4, for which Mal is an essential signalling component, 13 does not contribute to gastric tumourigenesis in gp130 F/F mice. 3 It will now be of great interest to determine whether the differential pro-tumourigenic role of MyD88 and Mal is restricted to TLR2 signalling in the gastric compartment, or if it will also apply to other tumour types (for example, colon, liver) in which TLR2, and for that matter TLR4, have been implicated.
